Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lucie Oberic

Showing results (31-40 of 65) with videos related to

Pageof 7
Sort By:
Bone Marrow Transplantation|February 12, 2022
Bendamustine-EAM versus R-BEAM after high-dose cytarabine-based induction in newly diagnosed patients with mantle cell lymphoma, a LYSA retrospective studyDomitille Costes-Tertrais, Thomas Hueso, Thomas Gastinne, et al.
Blood Cancer Journal|May 24, 2020
Combining gene expression profiling and machine learning to diagnose B-cell non-Hodgkin lymphomaVictor Bobée, Fanny Drieux, Vinciane Marchand, et al.
Annals of Neurology|November 28, 2024
Unveiling the Clinical and Imaging Signatures of Intravascular Lymphoma of the Central Nervous System: A Multicentric Cohort StudyElodie Berthet, Antoine Guillonnet, Caroline Houillier, et al.
Bone Marrow Transplantation|March 4, 2021
Oxaliplatin before autologous transplantation in combination with high-dose cytarabine and rituximab provides longer disease control than cisplatin or carboplatin in patients with mantle-cell lymphoma: results from the LyMA prospective trialBenoit Tessoulin, David Chiron, Catherine Thieblemont, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 18, 2023
Long-Term Follow-Up of Rituximab Maintenance in Young Patients With Mantle-Cell Lymphoma Included in the LYMA Trial: A LYSA StudyClémentine Sarkozy, Catherine Thieblemont, Lucie Oberic, et al.
Haematologica|December 17, 2020
Baseline SUVmax is related to tumor cell proliferation and patient outcome in follicular lymphomaCédric Rossi, Marie Tosolini, Pauline Gravelle, et al.
Hematological Oncology|May 31, 2020
Whole genome copy number analysis in search of new prognostic biomarkers in first line treatment of mantle cell lymphoma. A study by the LYSA groupYannick Le Bris, Florence Magrangeas, Anne Moreau, et al.
AIDS (London, England)|September 20, 2017
Outcomes for HIV-associated diffuse large B-cell lymphoma in the modern combined antiretroviral therapy eraCaroline Besson, Remi Lancar, Sophie Prevot, et al.
Cancer Medicine|May 11, 2022
Clinical presentation, outcome, and prognostic markers in patients with intravascular large B-cell lymphoma, a lymphoma study association (LYSA) retrospective studyAntoine Bonnet, Céline Bossard, Ludovic Gabellier, et al.
British Journal of Haematology|February 6, 2023
Lenalidomide maintenance fails to overcome the unfavourable prognosis of low NK-cell counts in rituximab-chemotherapy responsive elderly DLBCL patients: A LYSA group studyAsma Beldi-Ferchiou, Jean-Philippe Jais, Hervé Ghesquieres, et al.
Pageof 7

Showing results (31-40 of 65) with videos related to

Sort By:
Pageof 7
Bone Marrow Transplantation|February 12, 2022
Bendamustine-EAM versus R-BEAM after high-dose cytarabine-based induction in newly diagnosed patients with mantle cell lymphoma, a LYSA retrospective studyDomitille Costes-Tertrais, Thomas Hueso, Thomas Gastinne, et al.
Blood Cancer Journal|May 24, 2020
Combining gene expression profiling and machine learning to diagnose B-cell non-Hodgkin lymphomaVictor Bobée, Fanny Drieux, Vinciane Marchand, et al.
Annals of Neurology|November 28, 2024
Unveiling the Clinical and Imaging Signatures of Intravascular Lymphoma of the Central Nervous System: A Multicentric Cohort StudyElodie Berthet, Antoine Guillonnet, Caroline Houillier, et al.
Bone Marrow Transplantation|March 4, 2021
Oxaliplatin before autologous transplantation in combination with high-dose cytarabine and rituximab provides longer disease control than cisplatin or carboplatin in patients with mantle-cell lymphoma: results from the LyMA prospective trialBenoit Tessoulin, David Chiron, Catherine Thieblemont, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 18, 2023
Long-Term Follow-Up of Rituximab Maintenance in Young Patients With Mantle-Cell Lymphoma Included in the LYMA Trial: A LYSA StudyClémentine Sarkozy, Catherine Thieblemont, Lucie Oberic, et al.
Haematologica|December 17, 2020
Baseline SUVmax is related to tumor cell proliferation and patient outcome in follicular lymphomaCédric Rossi, Marie Tosolini, Pauline Gravelle, et al.
Hematological Oncology|May 31, 2020
Whole genome copy number analysis in search of new prognostic biomarkers in first line treatment of mantle cell lymphoma. A study by the LYSA groupYannick Le Bris, Florence Magrangeas, Anne Moreau, et al.
AIDS (London, England)|September 20, 2017
Outcomes for HIV-associated diffuse large B-cell lymphoma in the modern combined antiretroviral therapy eraCaroline Besson, Remi Lancar, Sophie Prevot, et al.
Cancer Medicine|May 11, 2022
Clinical presentation, outcome, and prognostic markers in patients with intravascular large B-cell lymphoma, a lymphoma study association (LYSA) retrospective studyAntoine Bonnet, Céline Bossard, Ludovic Gabellier, et al.
British Journal of Haematology|February 6, 2023
Lenalidomide maintenance fails to overcome the unfavourable prognosis of low NK-cell counts in rituximab-chemotherapy responsive elderly DLBCL patients: A LYSA group studyAsma Beldi-Ferchiou, Jean-Philippe Jais, Hervé Ghesquieres, et al.
Pageof 7